Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

NCT ID: NCT05461690

Last Updated: 2022-07-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2025-06-30

Brief Summary

The incidence of homologous recombination deficiency in metastatic triple negative breast cancer was 52%-59%，PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single-strand break repair pathways. Treatment with PARP inhibitors could represent a novel opportunity to selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. This is a multicenter, single-arm, phase II study evaluating the efficacy and safety of niraparib in patients with HRD positive metastatic triple negative breast cancer.

Detailed Description

Simon's two-stage optimization method is used to estimate the sample size. The first kind of error α Set to 0.1, type II error β Set to 0.25, P0 to 30%, P1 to 44%. 22 patients were enrolled in the first stage. If the number of effective cases ≤ 6, the trial was terminated. Otherwise, continue to enroll 26 patients in the second stage. If the number of effective cases in the two stages is ≤ 18, there is no need to further study the drug. Assuming an abscission rate of 5%, it is estimated that 50 subjects will be enrolled in the trial.

Conditions

Homologous Recombination Deficiency; Triple Negative Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Niraparib group

200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.

Group Type: EXPERIMENTAL

Niraparib

Intervention Type: DRUG

200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.

Interventions

Niraparib

200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.

Intervention Type: DRUG

Other Intervention Names

Zejula

Eligibility Criteria

Inclusion Criteria

1. Patient is female at least 18 years of age.

2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

3. Life expectancy longer than 6 months.

4. Patients with histologically confirmed metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (ie, TNBC).

5. Patient has measurable lesions by RECIST v1.1.

6. Patients has archival tumor tissue available or a fresh biopsy must be obtained prior to study treatment initiation for HRD test. The HRD test results must be positive (HRR mutation or/and HRD score≥42).

7. Patients had received no more than two previous chemotherapy regimens for metastatic disease, and they had received neoadjuvant or adjuvant treatment or treatment for metastatic disease with an anthracycline (unless it was contraindicated) or a taxane.

8. Previous neoadjuvant or adjuvant treatment with platinum or/and anthracycline were allowed if at least 6 months had elapsed since the last dose. Previous treatment with platinum or/and anthracycline for metastatic disease were allowed if there was no evidence that disease progression had occurred during treatment.

9. Patient has adequate organ function, defined as:

1. Absolute neutrophil count (ANC) ≥ 1,500/μL(growth factor support treatment shall not be used within 7 days after the start of study treatment）

2. Platelets ≥ 100,000/μL(platelet transfusion or any form of platelet raising therapy shall not be used within 2 weeks after the start of the study)

3. Hemoglobin ≥ 9 g/dL(blood transfusion shall not be used within 2 weeks after the start of study treatment. EPO support treatment shall not be used within 7 days after the start of study treatment.)

4. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN

5. Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN

6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN

7. Urine protein ≤ (+), or 24-hour urine protein quantity is less than 1g

8. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants

9. Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

10. Female patient has a negative serum pregnancy test within 7days prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons).

11. Female patients must agree not to breastfeed during the study period or within 180 days after the last dose of study treatment.

12. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.

Exclusion Criteria

1. Patients have received PARP inhibitors for metastatic breast cancer.

2. Patients who are concurrently participating in any interventional clinical trial and have received an investigational therapy ≤ 4 weeks prior to initiation of protocol therapy or within at least 5 elimination half-lives of the investigational drug.

3. Patients who have received radiotherapy with > 20% bone marrow coverage before treatment initiation, except for minor palliative radiotherapy within 1 weeks prior to enrollment.

4. Patients with visceral crisis requiring chemotherapy.

5. Patients with hypersensitivity to nilaparib.

6. Patients receiving blood transfusions (platelets or red blood cells) ≤ 4 weeks prior to starting protocol therapy.

7. Patients who have received colony-stimulating factors (eg, granulocyte-colony stimulating factor [g-CSF], granulocyte-macrophage colony-stimulating factor, or recombinant erythropoietin) 4 weeks prior to starting protocol therapy.

8. Known history of platelet transfusions for chemotherapy-induced thrombocytopenia or ≥ Grade 3 hematologic toxicity from prior cancer therapy (lasting > 4 weeks and associated with most recent therapy).

9. Patient has any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

10. Patient has a serious, uncontrolled medical condition, non-malignant systemic disease, or active, uncontrolled infection.

11. Patient has other types of cancer ≤ 2 years prior to starting protocol therapy.

12. Patients with symptomatic brain metastasis or leptomeningeal metastasis.

13. Patients with prior allogeneic bone marrow transplant or cord blood transplant.

14. Patients who cannot swallow oral medication.

15. Patients with gastrointestinal disorders that could interfere with absorption of the study drug.

16. Patient has a systemic active autoimmune disease (use of disease modifying agents, corticosteroids, or immunosuppressive agents, etc.) within the past 2 years.

17. Patients with a history of human immunodeficiency virus, active hepatitis B or C.

18. Female patients who are pregnant or lactating or adults of childbearing potential not using effective contraceptive methods.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: collaborator

Hunan Cancer Hospital

OTHER

Sponsor Role: collaborator

Fujian Cancer Hospital

OTHER_GOV

Sponsor Role: collaborator

Zhejiang University

OTHER

Sponsor Role: collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

OTHER

Sponsor Role: collaborator

Zhejiang Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

Wang Xiaojia

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xiaojia Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Zhejiang Cancer Hospital

Central Contacts

Xiaojia Wang, MD

Role: CONTACT

wxiaojia0803@163.com

13906500190

Wenming Cao, MD, PhD

Role: CONTACT

caowm@zjcc.org.cn

13858064001

Other Identifiers

IRB-2022-329

Identifier Type: -

Identifier Source: org_study_id